Bispecific antibody · Immune activation, directed at cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and lymphocyte activation gene 3 protein (LAG3) · developed by Xencor
Pavunalimab is an Fc-engineered bispecific antibody that binds the inhibitory checkpoint receptors CTLA-4 and LAG-3 on T cells in the tumor microenvironment. Dual blockade of these receptors is intended to enhance T-cell activation and proliferation. It is being studied in multiple solid tumors, including melanoma, lung, breast, gastric and ovarian cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05695898 | Phase 1 | Metastatic Melanoma | Terminated | XNCR |
| NCT03849469 | Phase 1 | Melanoma | Completed | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid TumorsCervical CarcinomaEpithelial Ovarian CancerGastric or Gastroesophageal Junction AdenocarcinomaHepatocellular CarcinomaMelanomaNasopharyngeal CarcinomaNon-small Cell Lung CarcinomaPancreatic CarcinomaProstate CarcinomaRenal Cell CarcinomaSmall Cell Lung CarcinomaSquamous Cell Carcinoma of the Head and NeckTriple Negative Breast Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →